HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Payne, E. H. Articles by Nickel, K. C. Search for Related Content PubMed Articles by Payne, E. H. Articles by Nickel, K. C.

Parenteral Use of Camoquin Hydrochloride as an Antimalarial

The authors recognize the need for a rapid acting parenteral antimalarial. Realizing that oral medication is the method of choice, there remains, however, many instances in which it is difficult or impossible for the patient to take drugs by mouth. Among these, we might mention the mental patient who is violent or contrary, the patient in coma suffering from pernicious malaria, or the patient who is vomiting.

Camoquin Hydrochloride⁴, (SN 10751), a new synthetic antimalarial, has been studied in order to determine its possibilities as a successful antimalarial for parenteral use. It is chemically known as 4(3'-diethylamino-methyl-4'-hydroxyanilino)-7-chloroquinoline dihydrochloride dihydrate. In crystalline form, it is light yellow in color and soluble in water in a 5 per cent concentration at room temperature. The synthesis of this drug was first reported at a meeting of the American Chemical Society in 1946 (1).

Various workers have checked the effectiveness of this drug against avian malaria.

⁴ Reg. U. S. Patent Office, Parke, Davis & Co.

¹ Dept. Clinical Investigation, Parke, Davis & Co., Detroit, Mich.

² Director, Dept. Clin. Invest., Parke, Davis & Co., Detroit, Mich.

³ Staff Physician, Ypsilanti State Hospital, Ypsilanti, Mich.